Testicular cancer is the most common cancer in men under the age of 45. The majority of tumours are germ cell tumours, but there are numerous other types, making testicular tumours one of the most diverse areas of human pathology, despite their relative rarity. The picture is complicated by the post-chemotherapy changes that are seen, as many tumours are treated by excision of residual disease, after metastasis has occurred.
The identification of pathological factors predictive of relapse in patients with disease apparently confined to the testis at presentation (clinical stage I) has meant that patients at low risk can be offered a range of options including surveillance, and for seminomas, adjuvant carboplatin is an increasingly popular option over radiotherapy in the UK. For patients with metastatic disease, international collaboration has led to the development of an International Consensus Classification, based on:
which has subsequently been adopted by the TNM classification system.
NB This document supersedes the 2007 edition, 'Dataset for histopathology reports for testicular tumours and post-chemotherapy residual masses'.